Open-to-Accrual Therapeutic Trials


Immune Therapy

Protocol ID
Official Title
PI Name
Lead CRC
Disease Site
Phase

11-C-0231

A Pilot Study to Test the Feasibility and Immunologic Impact of Sipuleucel-T (Provenge™) Administered with or without anti-PD-1 mAb (CT-011) and Low Dose Cyclophosphamide in Men with Advanced Castrate-resistant Prostate Cancer

S. Khleif

Robin Dobbins

Prostate Cancer

II

GO29753 (formerly NLG-9191)

ClinicalTrials.gov #: NCT02048709

A Phase I Study of GDC-0919 for Adult Patients with Recurrent Advanced Solid Tumors

S. Khleif

Robin Dobbins

Selected Solid Tumors

I

MEDI4736-1108

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors

S. Khleif

Robin Dobbins

Selected Solid Tumors

I

EMR 100070-001

A Phase I, Open-Lable, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indicators

S. Khleif

Lisa Marshall

Selected Solid Tumors

I

NLG-2102

A Phase I/II Study of the Combination of 1-Methyl-D-Tryptophan (Indoximod) and Temozolomide for Adults Patients with Temozolomide-Refractory Primary Malignant Brain Tumors

J. Janik

Chris Sanchez

Malignant Brain Tumors

I/II

NLG-2103

A Phase 1/2 Study of the Concomitant Administration of Indoximod plus Lpilimumab for Adult Patients with Metastatic Melanoma

S. Khleif

Robin Dobbins

Melanoma

I/II

NLG-2104

A Phase 1/2 Study of Indoximod in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas

A. Nayak

Robin Dobbins

Pancreatic Cancer

I/II

NLG-2105

A Phase I Trial of Indoximod in Combination with Temozolomide-Based Therapy for Children with Progressive Primary Brain Tumors

T. Johnson

Kimberly Gray

Primary Brain Tumors

I